Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(2 years from now) | |
US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(4 years from now) | |
US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(11 years from now) | |
US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET;ORAL